The value of a molecular diagnostic tool in patients with suspect pancreatic cancer

Accuracy of targeted Next-Generation Sequencing in the diagnostic process for pancreatic and periampullary cancer; a multi-center prospective cohort study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23289

Enrollment

Registered

2018-01-24

Start date

2017-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer Periampullary Cancer Pancreas kanker Periampullaire kanker

Interventions

The cytology material, obtained during fine-needle aspiration or brush, is analyzed with NGS, the molecular findings are integrated during the diagnostic process.

Eligibility

Inclusion criteria

Inclusion criteria: • Patient with suspect pancreatic or periampullary lesion (papil; duodenum; distal bile duct); or patients with suspect cysts • Sufficient radiological images; assessed by specialized radiologist • Sufficient clinical assessment; including bilirubine levels and CA19.9 levels • Cytology sample available for pathological assessment; either obtained with FNA, brush or punction from cystic wall

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of NGS	—

Secondary

Measure	Time frame
- Contribution of NGS to the diagnostic process. - Percentage of change of treatment type - Sensitivity and specificity	—

Contacts

Public ContactSven Mieog

j.s.d.mieog@lumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)